Insider Transactions in Q3 2023 at Zynerba Pharmaceuticals, Inc. (ZYNE)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2023
|
Armando Anido Chairman & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
17,830
-1.87%
|
$17,830
$1.33 P/Share
|
|
Sep 13
2023
|
Kenneth T Jones |
SELL
Open market or private sale
|
Direct |
2,505
-2.85%
|
$2,505
$1.33 P/Share
|
|
Sep 13
2023
|
James E Fickenscher Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,998
-2.32%
|
$8,998
$1.33 P/Share
|
|
Sep 13
2023
|
Brian Rosenberger VP, Commercial & Business Dev. |
SELL
Open market or private sale
|
Direct |
6,411
-2.5%
|
$6,411
$1.33 P/Share
|
|
Sep 13
2023
|
Terri B Sebree President |
SELL
Open market or private sale
|
Direct |
12,401
-2.04%
|
$12,401
$1.33 P/Share
|
|
Sep 12
2023
|
Armando Anido Chairman & Chief Exec. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,747
+6.35%
|
-
|
|
Sep 12
2023
|
Kenneth T Jones |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+9.28%
|
-
|
|
Sep 12
2023
|
James E Fickenscher Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+7.46%
|
-
|
|
Sep 12
2023
|
Brian Rosenberger VP, Commercial & Business Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
22,200
+7.98%
|
-
|
|
Sep 12
2023
|
Terri B Sebree President |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+6.88%
|
-
|